Myocardial ischaemia inhibits mitochondrial metabolism of 4-hydroxy-trans-2-nonenal.
Myocardial ischaemia is associated with the generation of lipid peroxidation products such as HNE (4-hydroxy-trans-2-nonenal); however, the processes that predispose the ischaemic heart to toxicity by HNE and related species are not well understood. In the present study, we examined HNE metabolism in isolated aerobic and ischaemic rat hearts. In aerobic hearts, the reagent [(3)H]HNE was glutathiolated, oxidized to [(3)H]4-hydroxynonenoic acid, and reduced to [(3)H]1,4-dihydroxynonene. In ischaemic hearts, [(3)H]4-hydroxynonenoic acid formation was inhibited and higher levels of [(3)H]1,4-dihydroxynonene and [(3)H]GS-HNE (glutathione conjugate of HNE) were generated. Metabolism of [(3)H]HNE to [(3)H]4-hydroxynonenoic acid was restored upon reperfusion. Reperfused hearts were more efficient at metabolizing HNE than non-ischaemic hearts. Ischaemia increased the myocardial levels of endogenous HNE and 1,4-dihydroxynonene, but not 4-hydroxynonenoic acid. Isolated cardiac mitochondria metabolized [(3)H]HNE primarily to [(3)H]4-hydroxynonenoic acid and minimally to [(3)H]1,4-dihydroxynonene and [(3)H]GS-HNE. Moreover, [(3)H]4-hydroxynonenoic acid was extruded from mitochondria, whereas other [(3)H]HNE metabolites were retained in the matrix. Mitochondria isolated from ischaemic hearts were found to contain 2-fold higher levels of protein-bound HNE than the cytosol, as well as increased [(3)H]GS-HNE and [(3)H]1,4-dihydroxynonene, but not [(3)H]4-hydroxynonenoic acid. Mitochondrial HNE oxidation was inhibited at an NAD(+)/NADH ratio of 0.4 (equivalent to the ischaemic heart) and restored at an NAD(+)/NADH ratio of 8.6 (equivalent to the reperfused heart). These results suggest that HNE metabolism is inhibited during myocardial ischaemia owing to NAD(+) depletion. This decrease in mitochondrial metabolism of lipid peroxidation products and the inability of the mitochondria to extrude HNE metabolites could contribute to myocardial ischaemia/reperfusion injury.
Hill
Bradford G
BG
Institute of Molecular Cardiology, Department of Medicine, University of Louisville, Louisville, KY 40202, U.S.A.
Awe
Sunday O
SO
Vladykovskaya
Elena
E
Ahmed
Yonis
Y
Liu
Si-Qi
SQ
Bhatnagar
Aruni
A
Srivastava
Sanjay
S
D000447:Aldehydes / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D008929:Mitochondria, Heart / Q000187:drug effects / Q000378:metabolism*; D015394:Molecular Structure; D017202:Myocardial Ischemia / Q000378:metabolism*; D010084:Oxidation-Reduction; D051381:Rats; D017207:Rats, Sprague-Dawley
D000447:Aldehydes; C027576:4-hydroxy-2-nonenal
Circ Res. 2003 Aug 22;93(4):292-301
12933700
J Neurochem. 1999 Apr;72(4):1617-24
10098869
J Biol Chem. 2004 Mar 19;279(12):11789-97
14699126
Circ Res. 1976 May;38(5 Suppl 1):I80-91
1269093
Biochemistry. 1985 Mar 26;24(7):1662-8
3159423
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1404-7
3029779
J Biol Chem. 1989 Nov 15;264(32):18890-5
2553726
Am J Pathol. 1990 Feb;136(2):273-83
2305831
Annu Rev Physiol. 1990;52:487-504
2184765
Free Radic Biol Med. 1991;11(1):81-128
1937131
Toxicol Appl Pharmacol. 1992 Dec;117(2):200-7
1471152
J Biol Chem. 1993 Sep 5;268(25):18532-41
8395507
Free Radic Biol Med. 1993 Aug;15(2):187-93
8397144
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8742-6
8378358
Circ Res. 1995 Feb;76(2):293-304
7834841
Circulation. 1995 Jun 1;91(11):2810-8
7758188
Drug Metab Rev. 2004 Oct;36(3-4):669-701
15554242
Mutat Res. 2005 Dec 11;591(1-2):34-44
16099477
J Biol Chem. 2006 Jun 2;281(22):15110-20
16567803
J Biol Chem. 2006 Jun 30;281(26):17652-60
16648138
Physiol Rev. 2007 Jan;87(1):315-424
17237348
Circ Res. 2007 Apr 13;100(7):1089-98
17363700
J Biol Chem. 2008 Apr 4;283(14):9101-12
18223294
J Mol Cell Cardiol. 1996 Aug;28(8):1759-67
8877785
Am J Physiol. 1995 Jul;269(1 Pt 2):H14-22
7631842
Mutat Res. 1995 Dec;335(3):259-65
8524341
J Biol Chem. 1996 Mar 15;271(11):6033-8
8626387
Circulation. 1996 Nov 1;94(9 Suppl):II398-406
8901781
Circulation. 1996 Nov 1;94(9 Suppl):II412-7
8901783
Circulation. 1996 Nov 15;94(10):2587-96
8921805
Am J Physiol. 1997 Sep;273(3 Pt 2):H1090-5
9321793
Circ Res. 2000 Feb 18;86(3):264-9
10679476
Free Radic Biol Med. 2000 Oct 1;29(7):642-51
11033416
Arch Biochem Biophys. 2001 May 1;389(1):77-83
11370675
J Biol Chem. 2001 Jan 26;276(4):2571-5
11073947
Arch Biochem Biophys. 2001 Jul 15;391(2):171-9
11437348
Atherosclerosis. 2001 Oct;158(2):339-50
11583712
Circulation. 2001 Dec 18;104(25):3158-67
11748117
Circulation. 2002 Feb 26;105(8):981-6
11864929
J Pharmacol Exp Ther. 2002 Aug;302(2):407-15
12130697
Circ Res. 2002 Aug 9;91(3):240-6
12169650
EMBO J. 2003 Aug 15;22(16):4103-10
12912909
Circulation. 1997 Nov 4;96(9 Suppl):II-216-20
9386101
Biochem J. 1998 Feb 1;329 ( Pt 3):469-75
9445372
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):510-4
9435222
J Biol Chem. 1998 May 1;273(18):10893-900
9556565
Chem Res Toxicol. 1998 May;11(5):535-43
9585485
J Mol Cell Cardiol. 1998 Nov;30(11):2281-9
9925365
Am J Physiol. 1999 Mar;276(3 Pt 2):H935-43
10070077
J Biol Chem. 2003 Oct 17;278(42):41380-8
12888579